Gene therapy for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy called EXG202 for wet age-related macular degeneration, a common cause of vision loss. The goal is to see if a single treatment can safely reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years of age or older.
- You must have wet age-related macular degeneration (AMD) with active disease in the study eye.
- The study eye should not have other eye diseases that could affect central vision, like diabetic retinopathy or high myopia.
- You must not have glaucoma or optic nerve damage that affects central vision in that eye.
- You must not have a history of retinal detachment in the study eye.
- You must agree to use effective contraception and not plan to donate sperm or eggs during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study tests an investigational gene therapy (called CRISPR/Cas13) given as an injection into the eye for people with wet age-related macular degeneration (nAMD). It aims to see if the treatment is safe and if it can help by targeting the cause of the disease.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This trial tests a gene therapy called LX109 for wet age-related macular degeneration (AMD), a condition where abnormal blood vessels damage the retina. The therapy aims to reduce the need for frequent eye injections by providing a longer-lasting treatment.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.